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We recently succeeded in purifying a monocyte chemotactic factor (MCF) from
the conditioned media of a myelomonocytic cell line (THP-1) (1). We have molecularly
cloned the cDNA of MCF (2), and shown that MCF, in addition to its monocyte
chemotactic activity, also activates monocytes to be more cytostatic against several
types ofhuman tumor cells in vitro (1). Therefore, we termed this molecule mono-
cyte chemotactic and activating factor (MCAF). Subsequently, MCAF has been shown
to be produced by several additional cell types, namely fibroblasts and endothelial
cells (3). We describe here that MCAF, which was purified from human fibrosarcoma
cell line-conditioned media, also induces superoxide anion and lysosomal enzyme
release from human monocytes and has potent in vivo monocyte recruitment activity.
Materials and Methods
Purification ofMCAF.
￿
Confluent fibrosarcoma cells, 8387 (4), were stimulated with 100
ng/ml rTNF-a in serum-free media overnight. The culture supernatants were centrifuged,
concentrated, and dialyzed against 0.05 M Tris-HCI, pH 7.5, before beingapplied to a 50-ml
heparin Sepharose column. MCAF was eluted with 0.05 M Tris-HCI, pH 7.5, containing
0.5 M NaCl. The eluate was further concentrated and loaded on to a gel filtration column
of Sephacryl S-200 (Pharmacia Fine Chemicals, Uppsala, Sweden), which was equilibrated
with D-PBS. The fractions containing monocyte chemotaxis activity in the molecular mass
rangeof 10-20kD were pooled and then applied to a carboxymethyl-silicagel column (7.5 x
150-mm CM-3SW) (Toyo Soda, Tokyo, Japan) connected to an HPLC system (2150; LKB
Instruments, Inc., Uppsala, Sweden). The starting buffer was 0.02 M 3-[N-morpholino] pro-
panesulfonic acid (MOPS), pH 6.5, and MCAF was eluted with a linear increase of salt con-
centration up to 0.5 M NaCl. Finally, samples were applied to a reverse phase chromatog-
raphycolumn (4.6 x 750-mm TMS-250 Ultropac column, 10,m; Toyo Soda) with the starting
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solvent, water containing 0.01 % trifluoroacetic anhydride (TFA) (Pierce Chemical Co., Rock-
ford, IL), and the limiting solvent, 60% acetonitrile (J. T Baker Chemical Co., Philipsburg,
NJ) in water containing 0.01% TFA.
Western Blotting Analysis ofMCAF.
￿
The samples were first separated on 15% SDS-PAGE
and electrophoretically transferred to a nitrocellulose membrane for 16 h at 100 mA using
0.025 M Tris-glycine buffer, pH 8.3. After the proteins were transferred to amembrane, MCAF
was reacted with the rabbit anti-MCAF antibody, which was generated by immunizing a
rabbit with synthetic MCAF (10th to 54th amino acid of mature MCAF) (1 :20 dilution),
followed by 1211-labeled protein A (4 p,Ci/20 ml). After extensively washing, the membrane
was dried and exposed to X-Omat AR film (Kodak, Rochester, NY) for 4 d at -70°C .
MCAF-ReceptorBindingAssay.
￿
THP-1-derived pure MCAF (1) was radiolabeled by mono-
iodinated Bolton-Hunter reagent, as previously described (5). In the binding inhibition assay,
107 monocyte-enriched mononuclear cells diluted in RPMI 1640 with 10 mg/ml BSA and
20 mM Hepes were added to a total volume of 200 p.l, then incubated in duplicate with "5I-
MCAF (-70,000 cpm/ng). Serial dilutions of unlabeled MCAF and rIL-8 (6) dissolved in
PBS containing 10% glycerol were added to the PBMC and incubated for 15 min at 37 °C.
After centrifugation, the cell pellet was resuspended in binding buffer, spun through 10%
sucrose in PBS, and the resulting pellet was assayed to determine the amount ofbound MCAF.
The percentage inhibition of binding of 1251-MCAF by unlabeled ligands was determined.
Intradermal Infection ofMCAF.
￿
20 Al of various concentrations of MCAF in PBS was in-
jected intradermally into the ears of 60 Lewis rats according to a randomized double blind
protocol. Gentamicin cream was placed over the needle puncture to prevent infection. Groups
of four rats for each of the five doses of MCAF (including PBS controls) were killed 3, 6,
and 18 h after injection. The ears were excised, fixed in 10% buffered formalin, processed
for routine histology, and stained with hematoxylin-eosin.
The number of neutrophils, lymphocytes, and monocytes/macrophages present in each
of eight 3-,um sections cut through injection sites from the ears of four rats were counted
on coded slides by light microscopy. Cells present in the two high-powered fields on either
side ofthe field containing the injection site were counted. The resultant data were analyzed
by regression analysis using the SAS General linear models procedure (PROC GLM, SAS,
1988, Version 6.03).
Monocyte chemotaxis assay, SDS-PAGE, superoxide anion assay, N-acetyl /3-D-glucos-
aminidase assay, and tumor growth inhibition assay were performed as described (1, 3, 7, 8).
Results
Purification ofMCAF.
￿
MCAF was purified to homogeneity from eight liters of
conditioned media from a TNFstimulated fibrosarcoma cell line, 8387, by sequen-
tial chromatography, including heparin-Sepharose affinity chromatography, gel filtra-
tion, carboxymethyl (CM)-HPLC, and reverse-phase (RP)-HPLC. The biological
activities ofeach fraction was monitored by both in vitro monocyte chemotactic ac-
tivity and (3-glucosaminidase-releasing activity. On C M-HPLC, MCAF was eluted
at -0.3 NaCl, corresponding to two distinct peaks (CM fractions 25 and 26, data
not shown). MCAF from each fraction was applied to RP-HPLC . As shown in Fig.
1, a and b, monocyte chemotactic activity and R-glucosaminidase-releasing activity
coeluted at a discrete absorbance peak located in both RP-HPLC eluates. We have
also confirmed that these two activitiescoeluted with monocyte cytostatic augmenting
activity (RP-HPLC ; Fig. 1), suggesting that all these activities are due to a single
molecular species. SDS-PAGE analysis ofthe purified MCAF showed microhetero-
geneity in molecular mass at -15 kD (Fig. 1 c). As shown in Fig. 1 d, all bands de-
tected on SDS-PAGE analysis showed the immunological reactivity with MCAF on
Western-blotting analysis. No endotoxin activity was detected by Limulus lysate assay
(<0.05 ng/ml). Fractions from CM 25, RP 21-22 contained 10.6 pg protein, andZACHARIAE ET AL.
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FIGURE 1 .
￿
Monocyte chemotactic activity, N-Acetyl /3-glucosaminidase release, andaugmenta-
tion of monocyte cytostatic activity against tumor cells at a 1 :1,000 dilution of fractions obtained
fromCM-HPLC (a) fraction 25 and (b) fraction 26 ; and runon a reverse-phase column . Absor-
bance is shown by the solid line. (c) SDS-PAGE of purified MCAF (1)CM 25, RP 21-22; and
(2)CM 26, RP 22-23 . Approximately 70-100 ng ofprotein was applied to a 15% polyacrylamide
gel followed by silver staining . (d) Western blotting of the purifiedMCAF : (1)CM 25, RP 21-22 ;
and (2) CM 26, RP 22-23 .
fractions from CM 26, RP 22-23 contained 6.8 leg protein, based on amino acid
composition analysis .
The identity ofthepurified MCAF from ahuman fibrosarcoma cell line with the
previously purifiedMCAF from ahumanmyelomonocytic cell line, THP-1, wasfurther
supported by specific inhibition of binding at 37°C of 125I-labeledMCAF obtained
from THP-1 to humanPBMC by the unlabeled fibrosarcoma-derived MCAF (Fig .
2) . Anotherbasic polypeptide chemoattractant, IL-8, at concentrations from 0.1 ng/ml
to 10 Ag/ml, failed to inhibit the binding of 125I-labeled MCAF to human PBMC
at 37°C .
In Vitro andIn Vivo BiologicalActivities ofPurledMCAF .
￿
The purifiedMCAF from
fractionCM 25, RP 21-22 and fractionCM 26, RP 22-23 was assayed formonocyte
chemotactic activity, N-acetyl a-glucosaminidase release, and superoxide anion re-
lease . The half-maximal monocyte chemotactic response occurred at doses of ti 1
ng/ml for both fractions, while the N-acetyl (3-glucosaminidase release showed an
EC5o of-3-5 ng/ml (data not shown) . MCAF was able to release superoxide anions
at concentrations >20 ng/ml. MCAF exhibited no chemotactic activity for neutro-
phils at any concentration tested (data not shown) .
To evaluate whether the purified MCAF also had in vivo cell recruitment effects,2180
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FIGURE 2 .
￿
Competition for the binding of 125I-MCAF
(THP-1 derived) to human PBMC by unlabeled purified
MCAF. (0)CM 25, RP 21-22 (10.6 pg/ml) ; (O)CM 26,
RP 22-23 (6.8 ug/ml) ; and (21) rIL-8 at different dilutions
was added together with 70,000 cpm (1 ng) "5I-MCAF and
incubated at 37°C for 15 min . The binding is expressed
as a percentage of binding obtained with 125-MCAF(THP-1
derived) alone (2,330 ± 187 cpm) . The data shown are rep-
resentative of two independent experiments .
serial dilutions ofMCAF in endotoxin-free PBS (fraction CM 25, RP 21-22) were
injected into the ears ofLewis rats at various times . MCAF showed selective mono-
cyte/macrophage recruitment activity in vivo when assayed at 3, 6, and 18 h. There
was a significant dose- and time-dependent accumulation of total leukocytes in the
perivenular connective tissue underlying the intradermal injection sites of purified
MCAF in the ears of Lewis rats . Dose-dependent accumulation wasfound formono-
cyte/macrophages (p = 0.002) but not for neutrophils (p = 0.18) or lymphocytes
(p = 0.14) at each of thetime points tested (data not shown) . No monocyte infiltra-
tion was detected at 3 min, 30 min, or90min after injection, regardless of the dose
of purified MCAF used (data not shown) . Fig. 3 A shows the site of PBS injection
at 18 h to contain asignificant macrophage infiltrate, but a sparse infiltration oflym-
phocytes and neutrophils. Fig . 3B showsthat 5.3 ng/ml ofMCAF induced amuch
more marked monocyte/macrophage infiltration at 18 h.
FGURE 3 .
￿
The histological appearance (x 175)
of rat ear dermis 18 h after injection of (A) 20
Al PBS and(B) 20 plMCAF(CM 25,RP 21-22),
at 5.3 ng/ml .PBS inoculation (A) results in vari-
able degrees of margination and infiltration
of neutrophils, lymphocytes, and monocytes,
whereasMCAF inoculation (B) produces marked
infiltration with monocyte/macrophages and few,
if any, neutrophils or lymphocytes .ZACHARIAE ET AL.
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Discussion
It is well established that a large number of tumors are infiltrated with macro-
phages (9). Themacrophages mayeither stimulate tumor growth throughtheproduc-
tion of growth factors or exert a suppressive effect through the production of
"macrophage-activating factors,"such as IFN-(3, TNF, IL-1, and MCAF. A number
oftumor-derivedcelllines havebeen shown toproduce monocytechemotactic factors
such as MCAF and related mediators (4). Such tumors are often infiltrated with
macrophages in vivo, which is associated with a better prognosis (4). MCAF may
contribute to inhibiting tumor growth by macrophages by attracting them to the
tumor site and subsequently activatingincreased cytostatic activity. Since IL-1 and
TNF induce MCAF production by certain tumor types as well as by normal fibro-
blasts and endothelial cells (3), the regulation ofMCAF production in tumor cells,
as well as in the connective tissues surrounding the tumor, may be regulated by lo-
cally produced IL-1 and TNF . Even though MCAF, unlike other cytokines such as
IFN-y and TNF, does not have a direct cytotoxic or cytostatic effect on tumor cells,
MCAF may play an important role in control oflocal tumor growth either by its
effect on monocytes or possibly by inducing other cytokines.
In this report, wehave shown that MCAF induced N-acetyl /3-D-glucosaminidase
and superoxide release, supporting the conceptthat MCAF is notmerely achemoat-
tractant for monocytes. Although the mechanism of augmentation of monocyte
cytostatic activity against tumor cells by MCAF is not yet known, it may be medi-
ated by lysosomal enzyme and/or superoxide anion release. IL-6, IL-1, and TNF
are not responsible forthisactivity ofMCAF, since MCAF does not induce mRNA
expression forIL-1-a/(3 or TNFac in monocytesinvitro, and antibodiesto
TNF, and IL-6 did not block the cytostatic effect of MCAF (1).
We are also the first to show that MCAF has potent monocyte recruitment ac-
tivity in vivo. This observation is consistent with and provides an explanation for
previous reports of acorrelation between monocyte chemotactic activity and mac-
rophagecontentoftumors (4). Monocyte accumulation atthe injection site ofMCAF
starts gradually at3 h andincreases up to 18 h. Thepotent invivomonocyte recruit-
ment activity ofMCAF supports thehypothesis that MCAF is involved in therecruit-
ment of monocytes to delayed-type hypersensitivity reaction sites.
We have also shown the specific binding of 125I-MCAF to human PBMC at 37°C.
Interestingly, another recently cloned chemoattractant, IL-8 (6), which has similar
biochemical characteristics, did not compete with 1251-MCAF in binding to mono-
cyte-enriched mononuclearcells, suggesting thatthere are distinct receptorsforMCAF
on human monocytes. The binding of 1251-MCAF does not occur at 4°C, but at
37°C, and starts rapidly with maximalbinding after 15 min. The bound molecules
are immediately internalized, asjudged by treating cells with 0.1 M glycine-HCI,
pH 3.0, 0.15 MNaCl buffered solution. This internalization can not be blocked by
either ATPsynthesisinhibitors (sodium azide; 2-4, dinitrophenol) or by transgluta-
minase inhibitors (bacitracin, monodansyl cadaverine). These phenomena are un-
usual for a polypeptide receptor, and, therefore, we have been unable to estimate
the number or the binding affinity ofthe receptor for MCAF on any cell type.
Summary
A monocyte chemotactic and activating factor (MCAF) has been purified from
TNFstimulated 8387 human fibrosarcoma cellline-conditioned media. Thepurified2182
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MCAF showed microheterogeneity yielding two bands on SDS-PAGE analysis.
Fibrosarcoma-derived MCAF specifically competed with THP-1 (a human mono-
cytic cell line)-derived 1251-labeled MCAF in binding to human PBMC, whereas
a similar basic heparin-binding leukocyte chemoattractant, IL-8, did not. The purified
MCAF stimulated superoxide anion and N-acetyl j3-D glucosaminidase-releasing
activity in human monocytes, as well as monocyte cytostatic augmenting activity
against tumor cells and chemotactic activity for monocytes. When injected subcutane-
ously into Lewis rat ears, the purified human MCAF also induced considerable in
vivo local monocyte infiltration beginning at 3 h and becoming maximal at 18 h.
In conclusion, the data presented in this paper indicate that MCAF is a potent acti-
vator ofmonocytes as well as a monocyte recruitment factorthat acts through receptors
that are specific for this novel molecule. This novel cytokine might have an impor-
tant role in tumor growth control due to its ability to attract and activate monocytes.
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